Mark Bloemendaal
Algemeen Directeur bij Observision BV
Profiel
Mark Bloemendaal is the founder of Observision BV, where he currently holds the title of Co-Chief Executive Officer since 2010.
He is also the founder of Angiogenesis Analytics BV, where he currently holds the title of Chief Executive Officer since 2018.
Mr. Bloemendaal is also the founder of Livassured BV.
In terms of education, Mr. Bloemendaal obtained an MBA from The Open University in 1997.
Actieve functies van Mark Bloemendaal
Bedrijven | Functie | Begin |
---|---|---|
Observision BV
Observision BV Miscellaneous Commercial ServicesCommercial Services Observision, the innovative market leader in security, presents a new generation of integrated security solutions, based on the company's own video and audio technology. With offices in the Netherlands and the United States, and in close cooperation with international systems integrators, they are able to solve highly complex security problems in existing and new (wireless) camera networks. Its customers operate in a wide range of sectors and include police forces, international airports, municipal governments for video surveillance, power stations and road, tunnel, bridge, high-voltage network and industrial complex operators. | Algemeen Directeur | 01-01-2003 |
Livassured BV
Livassured BV Electronic Equipment/InstrumentsElectronic Technology Livassured BV develops monitoring devices for epilepsy patients that identifies nocturnal seizures. The company was founded by Mark Bloemendaal and Asmund Tielens and is headquartered in Vught, the Netherlands. | Oprichter | - |
Angiogenesis Analytics BV
Angiogenesis Analytics BV Miscellaneous Commercial ServicesCommercial Services Angiogenesis Analytics BV is a Dutch company that aims to improve the diagnosis of prostate cancer by using artificial intelligence technology and ultrasound imaging. The company is based in 's-Hertogenbosch, Netherlands and was founded in 2018 by Mark Bloemendaal, who has been the CEO since then. The company's product, PCaVision, is an ultrasound-based computer aided diagnosis for prostate cancer. The company provides resources in their archive, including documentation of the PCaVision journey from the beginning, awards and grants, and journal articles and theses covering the science behind PCaVision. | Algemeen Directeur | 01-01-2018 |
Opleiding van Mark Bloemendaal
The Open University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Observision BV
Observision BV Miscellaneous Commercial ServicesCommercial Services Observision, the innovative market leader in security, presents a new generation of integrated security solutions, based on the company's own video and audio technology. With offices in the Netherlands and the United States, and in close cooperation with international systems integrators, they are able to solve highly complex security problems in existing and new (wireless) camera networks. Its customers operate in a wide range of sectors and include police forces, international airports, municipal governments for video surveillance, power stations and road, tunnel, bridge, high-voltage network and industrial complex operators. | Commercial Services |
Livassured BV
Livassured BV Electronic Equipment/InstrumentsElectronic Technology Livassured BV develops monitoring devices for epilepsy patients that identifies nocturnal seizures. The company was founded by Mark Bloemendaal and Asmund Tielens and is headquartered in Vught, the Netherlands. | Electronic Technology |
Angiogenesis Analytics BV
Angiogenesis Analytics BV Miscellaneous Commercial ServicesCommercial Services Angiogenesis Analytics BV is a Dutch company that aims to improve the diagnosis of prostate cancer by using artificial intelligence technology and ultrasound imaging. The company is based in 's-Hertogenbosch, Netherlands and was founded in 2018 by Mark Bloemendaal, who has been the CEO since then. The company's product, PCaVision, is an ultrasound-based computer aided diagnosis for prostate cancer. The company provides resources in their archive, including documentation of the PCaVision journey from the beginning, awards and grants, and journal articles and theses covering the science behind PCaVision. | Commercial Services |